Search Results

You are looking at 1 - 10 of 139 items for :

  • pharmacokinetics x
  • Clinical Medicine, other x
Clear All
Open access

Lenard Farczadi, Laurian Vlase, Orsolya Melles, Ramona Tolomeiu, Octavia Tamas-Krumpe, Andreea Buta and Laurentiu Ognean

References 1. Barrera B, Otero JA, Egido E et al. The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRP. Antimicrob Agents Chemother 2012; 56(7): 3535-3543. 2. Halferty L, Brennan GP, Trudgett A, Hoey L, Fairweather I. Relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Vet Parasitol 2009; 159:126–138. 3. González Canga A, Sahagún Prieto AM, José Diez Liébana M, Martínez NF, Vega MS, Vieitez JJ. The pharmacokinetics and metabolism of ivermectin in domestic animal

Open access

Sofiya L. Ivanova, Dimitrichka J. Dimitrova, Metodi H. Petrichev, Liliana I. Parvanova, Georgi Sl. Kalistratov and Lubomir T. Vezenkov

.0. Pharmacokinetic and Pharmacodynamic Data Analysis System for PC. Stuttgart, Jena, New York: Gustav Fisher; 1993. 18. Baggot DJ. The Physiological Basis of Veterinary Clinical Pharmacology. Oxford (UK): Blackwell Science Ltd; 2001. 19. Gibaldi M, Perrier D. Pharmacokinetics, Revised and Expanded. 2nd ed. Swarbrick J, editor. New York: Informa Healthcare Inc; 2007. 20. Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6:166-75. 21. Ivanova

Open access

Ioana Todor, Dana Muntean, Maria Neag, Corina Bocsan, Anca Buzoianu, Laurian Vlase, Daniel Leucuta, Ana-Maria Gheldiu, Adina Popa and Corina Briciu

References 1. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391-99. 2. B Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9. 3. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571-90. 4. Findling RL. Evolution

Open access

Diana Pop, Ana-Maria Gheldiu, Monica Oroian, Adriana Marcovici, Sandeep Bhardwaj, Arshad Khuroo, Ravi Kochhar and Laurian Vlase

, Lewis BC, et al. Identification of the human cytochromes P450 catalyzing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol. 2007;64(4):450-7. 15. Todor I, Muntean D, Neag M, et al. The influence of CYP2D6 phenotype on the pharmacokinetic profile of atomoxetine in Caucasian healthy subjects. Acta Medica Marisiensis. 2017;63(2):73-9. 16. Rojanasthien N, Autsavakitipong T, Kumsorn B, et al. Bioequivalence study of modified-release Gliclazide tablets in healthy volunteers. ISRN Pharmacol. 2012;2012. doi:10.5402/2012/375134. 17

Open access

Stoica Ciprian Mihai, Căldăraru Carmen Denise, Vari Camil Eugen, Tarţa Dorin Ionuţ, Dogaru Maria Titica, Caraşca Emilian and Dogaru Grigore Aloiziu

transplantation. Prilozi 2011;32:87-103. 12. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481–508. 13. Michael F. Crutchlow, Roy D. Bloom. Transplant-associated hyperglycemia: A new look at an old problem.Clin J Am Soc Nephrol 2007;2:343–355. 14. Pirsch J, Bekersky I, Vincenti F et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol 2000;40:527-532. 15. Hasselink DA, Ngyuen H, Wabbijin M et al

Open access

Suvatna Chulavatnatol, Kumthorn Malathum, Sasisopin Kiertiburanakul, Kittisak Sripha and Pojawon Lawanprasert

. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother. 1998; 42:332-8. 5. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 1998; 42:2784-91. 6. The United States Pharmacopoeial Convention, Inc. The United States Pharmacopeia 26 / National Formulary 21. Rockville, USA; 2003. 7. Drug Control Division. Thailand Guidelines for the Conduct of

Open access

Mona Fathi, Sohrab Kazemi, Farbod Zahedi, Mohamad Reza Shiran and Ali Akbar Moghadamnia

.: Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharm. 1977;11:283. 9. Srinath K, et al.: Formulation and evaluation of effervescent tablets of paracetamol. INT J Pharm Res Dev. 2011;3:76. 10. Blagden N, et al.: Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007 Jul 30;59(7):617-30 Epub 2007 May 29. 11. De Silva L, et al.: Usability of mobile technology to screen for drugdrug interactions in kidney transplant patients. Am J Nephrol

Open access

Monchana Jullangkoon, Sutep Jaruratanasirikul and Nanchanit Aeinlang

References 1. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother. 2004; 53:290-6. 2. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994; 47:471-505. 3. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007; 7

Open access

Olivera Z. Milovanović

;72(1):213-5. 60. Milovanovic O, Milovanovic JR, Djukic A, et al. Population pharmacokinetics of 25-hydroxyvitamin D in healthy young adults. Int J Clin Pharmacol Ther 2015;53(1):1-8. 61. Gerova DI, Galunska BT, Ivanova II, et al. Prevalence of vitamin D deficiency and insufficiency in Bulgarian patients with chronic hepatitis C viral infection. Scand J Clin Lab Invest 2014;74(8):665-72. 62. Borissova AM, Shinkov A, Vlahov J, et al. Vitamin D status in Bulgaria--winter data. Arch Osteoporos 2013;8:133. 63. Laktasić-Zerjavić N

Open access

Dan Andonie, Zsolt Gáll, Paul Bosa, Maria Titica Dogaru and Szende Vancea

carbamazepine in serum and saliva samples by high performance liquid chromatography with ultraviolet detection Odre đ ivanje karbamazepina u uzorcima seruma i salive primenom te č ne hromatografije visokih performansi sa ultravioletnom de. Vojn Pregl . 2009;66:347-352. 18. Krasowski MD, McMillin GA. Advances in anti-epileptic drug testing. Clin Chim Acta . 2014;436:224-236. 19. Beig A, Dahan A. Quantification of carbamazepine and its 10,11-epoxide metabolite in rat plasma by UPLC-UV and application to pharmacokinetic study. Biomed Chromatogr . 2014